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Osteosarcoma is the most common malignant bone neoplasia occurring in young patients in the first two decades of life, and
represents 20% of all primitive malignant bone tumours. At present, treatment of metastatic osteosarcoma is unsatisfactory. High-
dose chemotherapy followed by CD34+ leukapheresis rescue may improve these poor results. Neoplastic cells contaminating the
apheresis may, however, contribute to relapse. To identify markers suitable for detecting osteosarcoma cells in aphereses we
analysed the expression of bone-specific genes (Bone Sialoprotein (BSP) and Osteocalcin) and oncogenes (Met and ErbB2) in 22
patients with metastatic osteosarcoma and six healthy stem cell donors. The expression of these genes in aphereses of patients
affected by metastatic osteosarcoma was assessed by RT–PCR and Southern blot analysis. Met and Osteocalcin proved to be not
useful markers since they are positive in aphereses of both patients with metastatic osteosarcoma and healthy stem cell donors. On
the contrary, BSP was expressed at significant levels in 85% of patients. Moreover, 18% of patients showed a strong and significantly
positive (seven to 16 times higher than healthy stem cell donors) ErbB2 expression. In all positive cases, neoplastic tissue also
expressed ErbB2. Our data show that ErbB2 can be a useful marker for tumour contamination in aphereses of patients affected by
ErbB2-expressing osteosarcomas and that analysis of Bone Sialoprotein expression can be an alternative useful marker.
British Journal of Cancer (2003) 88, 396–400. doi:10.1038/sj.bjc.6600735 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: osteosarcoma; apheresis; ErbB2; bone sialoprotein; tumour marker
                                               
Osteosarcoma, the most common malignant bone neoplasia
occurring in the first two decades of life, is frequently associated
with alterations of Rb (Benedict et al, 1988), p53 (Varley et al,
1997), mdm2 (Wunder et al, 1999), c-myc (Gamberi et al, 1998), c-
fos (Wu et al, 1990) and other genes. However, aetiology and
molecular mechanisms underlying osteosarcoma remain unclear.
Metastasis, an early event in high-grade osteosarcoma history, is
the major cause of morbidity and mortality. At present, treatment
of high-grade metastatic osteosarcoma is unsatisfactory as 5 years
overall survival is only 20–25%. Increase of dose intensity of
chemotherapeutic agents (high-dose chemotherapy) may improve
these poor results, but it is associated with an increase of
haematological and systemic toxicity (Santana et al, 1992). Recent
use of haemopoietic growth factors has allowed, on one hand, the
reduction of interval and intensity of neutropenia and, on the
other, the possibility to harvest an adequate number of mobilized
stem cells that, reinfused after myeloablative treatment, can induce
a faster haemopoietic recovery (Fagioli et al, 2000). Reinfusion of
stem cells has, however, generated concern about the possibility of
contamination by neoplastic cells rescued from aphereses.
Although it is not yet known whether relapse is because of
endogenous reinfused cells, it is certainly important to investigate
tumour contamination in leukaphereses.
Our aim was to find markers for detecting osteoblastic
osteosarcoma cells in leukaphereses of patients with metastatic
osteosarcoma. Unfortunately, neither specific translocation nor
tumour-associated antigens have yet been described for this
tumour. We therefore tried to assess the circulating tumour
burden in patients with osteosarcoma metastatic at diagnosis. This
was carried out by evaluating the expression of two kinds of
molecules on cells derived from apheretic procedures: (a) Bone
Sialoprotein (BSP) and Osteocalcin that are produced by bone
cells, histotypically similar to osteosarcoma cells; (b) oncogenes
like MET or ErbB2, frequently overexpressed in osteosarcomas.
Bone Sialoprotein is a 80kDa extracellular matrix protein,
mainly produced and secreted by osteoblasts (Bianco et al, 1991).
BSP overexpression has been demonstrated also in breast
(Bellahcene et al, 1994) and in prostate cancer (Waltregny et al,
1998) in which BSP overexpression is strongly associated with
poor prognosis. Osteocalcin is a 5.8kDa (Thiede et al, 1994)
extracellular matrix bone protein of still unknown function,
selectively produced by mature osteoblasts. Met is the transmem-
brane tyrosine kinase receptor for hepatocyte growth factor (HGF).
It is overexpressed in 60% of osteosarcomas (Ferracini et al, 1995)
and in many other tumours such as colon (Di Renzo et al, 1995),
gastric (Carneiro and Sobrinho-Simoes, 2000; Lee et al, 2000) and
renal (Schmidt et al, 1997) carcinomas. ErbB2 is a 185kDa tyrosine
kinase receptor of the EGF receptor family (Samanta et al, 1994).
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sarcomas (Gorlick et al, 1999) and in many other tumours such as
breast (Pegram and Slamon, 2000), ovary (Slamon et al, 1989),
lung (Scheurle et al, 2000) and gastric (Lin et al, 2000) carcinomas.
Expression of ErbB2 in localised and metastatic osteosarcomas has
been associated with poor prognosis in terms of survival,
development of metastasis and response to chemotherapy (Onda
et al, 1996; Pegram and Slamon, 2000).
As all the analysed markers are illegitimately expressed in
haemopoietic cells (Chelly et al, 1989), we considered a
semiquantitative approach using RT–PCR followed by Southern
blot analysis, with a final quantification of radioactive intensity.
In this work, we show that Met and Osteocalcin are not useful
markers for the detection of micrometastasis in aphereses of
patients with metastatic osteosarcoma, as they are expressed at
significant levels also in healthy donors. On the contrary, we show
that BSP expression is significantly increased in patients. We then
show that cells derived from apheretic procedures express ErbB2 at
significant levels in patients with metastatic osteosarcomas in
comparison with healthy stem cell donors. Finally, we show that
different aphereses from the same patient display diverse ErbB2
levels.
MATERIALS AND METHODS
Patients and healthy donors
All patients and healthy stem cell donors gave written informed
consent for leukapheretic procedures.
Experiments on Osteocalcin and BSP were carried out using
leukaphereses from 14 patients. Expression of ErbB2 was evaluated
on the same leukaphereses plus a further eight samples from
patients successively recruited. All patients had histologically
confirmed metastatic osteosarcoma, before apheresis collection
(median age 12.8 years, range 6–34 years). Sites of primary
osteosarcoma were femur, humerus, tibia and fibula (see Table 1).
All patients had been treated with chemotherapy (following
methodology described in Fagioli et al, 2002) prior to apheresis
collection. As no primary tumours were available, ErbB2 expres-
sion was evaluated on lung metastases excised from patients
undergoing surgery. Six aphereses from healthy stem cell donors
were used as control. Healthy stem cell donors were siblings of
patients with acute lymphoblastic leukaemia undergoing allogenic
transplantation. Both osteosarcoma patients and healthy stem cell
donors were treated with granulocyte colony-stimulating factor
(G-CSF) before stem cell harvesting.
RNA extraction, RT–PCR and Southern blot experiments
Mononucleated cells were isolated by Ficoll from 1ml of
leukapheresis from individuals treated with G-CSF, obtaining a
number of cells included between 10
7 and 2 10
7. RNAs were
purified with the ULTRASPEC II RNA kit (Biotecx Houston, TE,
USA) based on extraction with guanidine and urea salts. DNA and
proteins were separated by phenol–chloroform, then RNA was
precipitated with ethanol 75%. RNA was finally eluted in DEPc
(diethylpyrocarbonate) containing water. A measure of 1mgo f
RNA was retro transcribed using the Promega kit (Madison, WI,
USA). In all, 100ng of cDNA was used for RT–PCR experiments.
All PCR reactions were conducted in a 50ml final volume:
Sterile water: 33.5ml
Buffer 10 +MgCl2 25mM
 1:5ml (Dynazyme)
DNTPs 2.5mM:5ml
 1
Primer sense: 30pm in 1ml
Primer antisense: 30pm in 1ml
Taq polymerase Dynazyme (2Uml
 1): 0.5ml
cDNA: 100ng in 4ml.
To quantify cDNA and to verify the absence of degradation, we
performed PCR amplification of mRNAs coding either for GAPDH
or b-actin, ubiquitously expressed proteins. All PCR experiments
were preceded by a 2-min denaturation at 941C and followed by a
5-min final extension at 721C. Thermal profile for GAPDH
amplification: 30 cycles starting with denaturation of 1min at
941C, followed by 30s of annealing at 541C, 40s of extension at
721C. Thermal profile for b-actin amplification: 30 cycles starting
with denaturation 1.5min at 941C, followed by 30s at 601C, and
1min of extension at 721C. Thermal profile for BSP amplification:
30 cycles starting with denaturation 1min at 941C, followed by 30s
of annealing at 551C, and 40s of extension at 721C. Thermal profile
for ErbB2 amplification: 30 cycles starting with denaturation 30s at
941C, followed by 30s of annealing at 541C, 40s of extension at
721C.
Thermal profile for Osteocalcin amplification: 30 cycles starting
with denaturation 30s at 941C, followed by 30s of annealing at
551C, 40s of extension at 721C.
All PCR products were analysed by radioactive Southern blot
using specific labelled probes. Radioactivity was quantified with a
STORM phosphor reader.
ErbB2 sense primer is located on exon 3; ErbB2 antisense primer
is located on exon 5.
Cell lines and cultures
U20S, SAOS II (available from ATCC catalogue), IOR/OS17, SARG,
MOS, (obtained from Istituto Ortopedico Rizzoli di Bologna) were
used as positive controls. U20S: human cell line from a
Table 1 Patient characteristics
Sex
Females 9
Males 13
Age
Median 12 years, 8 months
Range 6 years, 2 months–34 years, 10 months
Histology
Osteoblastic 13
Fibroblastic 4
Chondroblastic 3
Teleangectasic 1
Chondro-osteoblastic 1
Site at diagnosis
Humerus 3
Fibula 5
Femur 8
Tibia 5
Fibula+tibia 1
Site of MTS
Lung 21
Lung+pelvis 1
GAPDH: sense 50-ACC ACA GTC CAT GCC ATC AC-30 (Tm=57.41C)
antisense: 50-TCC ACC ACC CTG TTG CTG TA-30 (Tm=57.41C)
b-actin: sense: 50-TGA CGG GGT CAC CCA CAC ACT GTG CCC ATC
CA-30 (Tm 73.91C)
antisense: 50-CTA GAA GCA TTT GCG GTG GAC GAT GGA
GGG-30 (Tm 68.81C)
Osteocalcin: sense 50-TCC CAC AGA TTC CTC TTC TGG A-30 (Tm 59.31C)
antisense 50-GAT GGG CAT TTT GCA CGG G-30 (Tm 58.21C)
BSP: sense: 50-GCA TCG AAG AGT CAA AAT AG-30 (Tm 60.81C)
antisense 50-TTC TTC TCC ATT GTC TCC TC-30 (Tm 58.81C)
ErbB2: sense 50-CAC AGA CAC GTT TGA GTC CA-30 (Tm 56.81C)
antisense 50-AAA GCT CTC CGG CAG AAA TG-30 (Tm 56.81C)
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osteosarcoma. IOR/OS17, SARG, MOS: human cell lines from
osteoblastic osteosarcoma. All cell lines, were cultured in
Dulbecco’s modified essential medium (DMEM, GIBCO (Tulsa,
OK, USA)) supplemented with 10% foetal bovine serum, 1%
glutamine, penicillin streptomycin fungizon (PFS). All cell lines
were grown at 371C, in a CO2 5% atmosphere.
RESULTS
Osteocalcin and Met are expressed at comparable levels in
aphereses of patients and healthy stem cell donors
To detect tumour cells in aphereses of patients affected by
metastatic osteosarcoma, we investigated the expression of the
genes encoding for Osteocalcin and Met. Osteocalcin is a bone-
specific protein localised in the extracellular matrix; Met, the
tyrosine kinase receptor for HGF, is not expressed in osteoblasts,
but is ectopically expressed in 60% of osteosarcomas.
Using semiquantitative RT–PCR, we analysed Osteocalcin and
Met expression in aphereses of healthy stem cell donors and
patients. As shown in Figure 1, Osteocalcin expression is elevated
both in osteosarcoma patients and in healthy haemopoietic stem
cell donors, without any significant difference between the two
groups. The same results were obtained from the analysis of Met
expression (data not shown). These data show that neither
Osteocalcin nor Met are useful markers for the detection of
tumour contamination.
Average BSP expression is increased in patients affected by
metastatic osteosarcoma
BSP is an extracellular bone matrix protein that is mainly
expressed by osteoblasts. It has also been shown that its expression
is increased in prostate carcinomas where it is strongly associated
with poor prognosis (Waltregny et al, 1998). We first showed that
BSP mRNA is expressed in human osteosarcoma cell lines
(Figure 2A). On this premise, we compared BSP expression in
aphereses of patients and of healthy haemopoietic stem cell donors
by RT–PCR, followed by Southern blot. While control mRNA
(GAPDH) levels are comparable, there is a significant difference in
average BSP expression between the two groups. To measure the
differences observed in Southern blot analysis, we quantified
radioactivity of the bands by STORM phosphor reader and
calculated the ratio between BSP and GAPDH values. Average
BSP levels are 2.14 times higher in patients vs healthy donors.
Moreover, 85% of patients (12 out of 14) display significantly
higher BSP levels than all healthy donors (Figure 2B).
ErbB2 is a useful marker for detection of tumour
contamination in patients with ErbB2 expressing
osteosarcomas
The fourth marker we analysed is ErbB2. The ErbB2 gene,
encoding for a tyrosine kinase of the EGF receptor family, is
overexpressed in about 30% of human osteosarcomas and its
expression correlates with a poor prognosis. We measured the
levels of ErbB2 expression in patients and in healthy stem cell
donors by RT–PCR followed by Southern blot. While levels of b-
actin are comparable in patients and in donors, there is a
remarkable difference in ErbB2 expression between the two
groups. To quantify these differences, we measured radioactivity
of the amplified bands and, for each sample, we calculated the ratio
between ErbB2 and a control mRNA (b-actin). In all, 18% (four out
of 22) of patients displayed levels higher than all controls. Positive
patients showed values from seven to 16 times higher than healthy
donors (Figure 3).
To demonstrate that ErbB2 expression in aphereses may be
because of the presence of metastatic cells, we evaluated ErbB2
expression in lung metastasis derived from patients displaying
high levels of ErbB2 in aphereses. As shown in Figure 4, ErbB2
expression was evident in neoplastic tissues derived from these
patients (samples 6, 7 and 22), but not in those derived from
patients whose aphereses were negative.
Moreover, to evaluate if consecutive aphereses derived from the
same patient display the same level of tumour contamination, we
performed analysis of expression of ErbB2. As shown in Figure 4B,
patients ErbB2+ displayed different values of ErbB2 in different
aphereses. This observation suggests that the choice of the
apheretic collection for reinfusion could decrease the risk of
metastatic contamination.
DISCUSSION
At present, treatment of high-grade metastatic osteosarcoma
is unsatisfactory as 5 years overall survival is only 20–25%.
Increase of dose intensity of chemotherapeutic agents (high-dose
C 1 2 3 4 5 6 7 8 9 10 11 12 13 14 A   B   C   D   E   F
Osteocalcin
GAPDH
Figure 1 RT–PCR performed with osteocalcin-specific (upper panel)
and GAPDH-specific (lower panel) primers on cDNAs obtained from 14
patients affected by metastatic osteosarcoma and six healthy haemopoietic
stem cell donors. C: MG63 osteosarcoma cell line; 1–14: patient cDNAs;
A–F: stem cell donors cDNAs. This and all the following experiments were
done at least three times.
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Figure 2 (A) cDNA amplification from human osteosarcoma cell lines
with oligonucleotides specific for BSP. The size of the amplified fragment is
534b. Os10, Mos, U2OS, MG63, Sarg: human osteosarcoma cell lines. (B)
Schematic representation of the ratio between BSP and GAPDH
expression in stem cell donors and in patients (for experimental details
see the Materials and Methods section). A–F: stem cell donors; 1–14:
patients affected by metastatic osteosarcoma.
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with an increase of haematological toxicity. Recent use of
haemopoietic growth factors has allowed the reduction of
neutropenia and has given the possibility of mobilising and
harvesting an adequate number of haemopoietic CD34+ stem cells
(Fagioli et al, 2002). Purified CD34+ stem cells, once reinfused
after myeloablative treatment, can induce a faster haemopoietic
recovery. However, reinfusion of stem cells has generated concern
about the possibility of rescuing neoplastic cells contaminating the
aphereses. Even if it is not yet known whether relapses are because
of endogenous or reinfused cells, it is certainly important to
investigate tumour contamination in leukaphereses.
Our objective was to find markers able to detect osteoblastic
osteosarcoma contamination in aphereses of patients with meta-
static osteosarcoma. Since, as yet, no specific antigen has been
found for osteosarcoma, in order to reveal the presence of
metastatic osteosarcoma cells, we looked for cells expressing either
bone-specific markers or oncogenes that have been shown to play
a role in osteosarcoma development. Among the markers
belonging to the first group we analysed BSP and Osteocalcin;
among the oncogenes described to play a role in osteosarcoma
progression, we evaluated Met and ErbB2.
Our data indicate that neither Met nor Osteocalcin are useful
markers to detect metastatic cells since they are expressed at
comparable levels in aphereses of patients with metastatic
osteosarcoma as well as those of healthy stem cell donors.
We obtained more interesting results with BSP, a protein
produced by osteoblasts, whose expression is increased in
osteosarcoma patients; nevertheless, quantitative difference be-
tween the two groups is not wide enough to use this molecule as a
single marker in the detection of peripheral micrometastasis. On
the contrary, since this molecule is expressed in the vast majority
of primary osteosarcomas, its additional evaluation might be
helpful for further characterization of patients.
The last molecule we considered for the detection of tumour
contamination is ErbB2, a tyrosine kinase receptor of the EGF
receptor family. Even if this is not a tumour-specific marker, it is
overexpressed in 30% of osteosarcomas and it is associated with
poor prognosis (Gorlick et al, 1999). In our experiments, we found
that 18% of aphereses derived from patients affected by
osteosarcoma were significantly positive for ErbB2 expression;
lung metastasis derived from these same patients were also
positive for ErbB2 expression. It is also important to point out that
positivity of the apheresis was detected only in patients whose
neoplastic tissues express ErbB2.
We can thus conclude that, although finding low ErbB2 levels
does not exclude neoplastic bone marrow contamination, high
levels of ErbB2 expression in aphereses might be evocative of
micrometastasis. Another conclusion that can be drawn by this
work is that aphereses obtained by the same patient can display a
different degree of ErbB2 expression. It might be thus critical,
when possible, to analyse the level of expression of ErbB2, to avoid
reinfusion of blood cells contaminated by ErbB2+ cells. Moreover,
if reinfusion of these positive aphereses is required, the possibility
of purging them by use of anti-ErbB2 antibodies should be
considered.
ErbB2 has been extensively studied for its involvement in
different human tumours, such as breast cancer. Since also in these
cases overexpression of this gene correlates with a poor prognosis,
therapeutic approaches have been pursued to either decrease
ErbB2 expression or functionally inactivate it. In fact, few years
ago a monoclonal anti-ErbB2 antibody (Herceptin) became
available and was used to treat patients with metastatic breast
cancer; these trials showed a significant improvement of patient’s
outcome following this treatment (Piccart and Awada, 2000;
Stebbing et al, 2000). If our data will be confirmed on larger
numbers, it can be hypothesized that a similar application of
Herceptin in ErbB2 overexpressing osteosarcomas could also
result in treatment improvement. Moreover, many other ther-
apeutical approaches targeting this molecule are under develop-
ment, such as the use of monoclonal anti-ErbB2 antibodies
conjugated with cytotoxic drugs (Azemar et al, 2000) single-chain
antibodies, and DNA vaccines (Wei et al, 1999).
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Figure 3 Schematic representation of the ratio between ErbB2 and b-
actin expression in stem cell donors and in patients. A–F: stem cell donors;
1–22: patients affected by metastastic osteosarcoma. Patient numbering is
the same as in Figure 2B.
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Figure 4 (A) RT–PCR performed with ErbB2-specific (upper panel)
and b-actin-specific (lower panel) oligonucleotides. cDNAs were obtained
from metastasis of nine patients. C: cDNA from MG63 osteosarcoma cell
line. Patient numbering is the same as in Figure 3. (B) Schematic
representation of the ratio between ErbB2 and b-actin expression in
different aphaereses derived from ErbB2+ patients (patient numbering
corresponds to Figure 3).
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